BSEM targets Nasdaq with 97 percent margins and 25.50 analyst price target

Unsubscribe

A message from Huge Alerts

BSEM Just Released Publication of Its Audited Financial Statements for Fiscal Years 2024 and 2025—Fast-Tracking a High-Profile Nasdaq Uplisting!

BioStem Technologies (OTCQB: BSEM) is rapidly evolving from a niche regenerative medicine innovator into a full-scale MedTech growth story.

The company’s recent acquisition of BioTissue Holdings’ surgical and wound care business for up to $40 million not only broadens its market from physician offices into hospitals and surgical centers but also immediately adds $29 million in revenue and a seasoned national sales team.

Coupled with the proven BioREtain® technology and breakthrough clinical results demonstrating superior wound closure rates, BSEM is now uniquely positioned to address a $300–$350 million total addressable market.

On the financial front, BSEM continues to impress. Q4 revenue topped $10 million with nearly best-in-class gross margins of 97%, and adjusted EBITDA remained solid at $3.4 million despite temporary headwinds. Importantly, the company has published its audited 2024–2025 financials, a key milestone toward its highly anticipated Nasdaq uplisting in 2026.

This move promises increased liquidity, institutional investor interest, and higher valuation potential. With analysts assigning a $25.50 price target, BSEM’s combination of earnings strength, strategic expansion, and regulatory readiness underscores a rare small-cap investment story with multiple growth levers.

BioStem just hit a critical milestone with its audited financials. See how this could set the stage for a NASDAQ uplisting soon!


Exclusive Article

Is Reddit’s Stock Collapse a Buying Opportunity?

By Jessica Mitacek. First Published: 3/22/2026. 

Reddit logo displayed in a modern office amid market focus on the company’s stock decline and potential buying opportunity.

Key Points

  • Shares of Reddit are down 43% this year, but the platform is experiencing a surge in users and ad revenue.
  • The company’s earnings remain strong, with seven consecutive quarterly beats as well as revenue growth of 69% last year.
  • The average 12-month analyst price target suggests that shares of RDDT could see massive potential upside to the tune of 78%.
  • Special ReportTicker Revealed: Pre-IPO Access to “Next Elon Musk” Company (From Banyan Hill Publishing)

Almost exactly two years after its initial public offering (IPO), Reddit (NYSE: RDDT) is one of the hardest-hit mid-cap stocks this year.

The decline began last October, when reports surfaced that ChatGPT was reducing its reliance on Reddit for sourcing content for generative responses. The Q4 2025 tech stock sell-off, which carried into 2026, further pressured the shares.

Why Invest in Med-X Before the Planned Nasdaq Listing? (Ad)

Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX) – and for investors, the biggest potential upside comes before the bell rings.

Med-X is a botanical pesticide company replacing chemical toxins with proven, plant-based solutions. With $6.4M in sales, no long-term debt, and expanding into 41 markets, the company is positioned to capture the surge in global demand for safer pest control.

As the world shifts to sustainable solutions, early investors could benefit from the same type of market recognition that transformed sectors led by innovators like Tesla and Zoom – only this time, in clean pest control.

Simpler. Safer. More Effective Pesticides.Become a Med-X shareholder at $4 per share before the Nasdaq plans unfold…

Today, shares of the online social news aggregation, discussion, and content-sharing platform are down more than 43% year-to-date (YTD) and nearly 48% from their all-time high on Sept. 19, 2025.

But for current shareholders and prospective investors, there are several reasons to be optimistic about the stock’s outlook.

Breakout 2025 Results Set Up a Confident 2026 Outlook

Advertising is Reddit’s primary revenue driver, and 2025 was a standout year for the company.

In Q4 alone, ad revenue grew 75% year-over-year (YOY) to $690 million. Lower-funnel performance was also notable, with conversion volumes doubling.

These results, among other factors, supported stronger capital allocation and guidance. Reddit’s board authorized a $1 billion share repurchase program, and the company issued Q1 2026 revenue guidance of $595 million to $605 million—roughly 53% YOY growth.

Guidance also included adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $210 million to $220 million, following a staggering 200% YOY EBITDA increase in 2025.

The gains reflect a growing user base. In his earnings call comments, cofounder and CEO Steve Huffman said Reddit welcomed over 121 million daily active users in Q4—up 19% YOY—and more than 471 million weekly active users, up 24% YOY.

Huffman also emphasized that the platform increasingly attracts users who want to “connect, learn, and research,” calling Reddit “the most human place on the internet…in a world flooded with AI slop.”

Ultimately, a larger user base draws more advertiser interest, which is fueling both top- and bottom-line growth at a record pace.

Checking Under the Hood: Reddit’s Financials Fuel the Bull Case

When the company reported full-year and Q4 2025 financials in February, it posted quarterly revenue above $725 million—a record for Reddit—and well ahead of analyst expectations of about $666 million.

Revenue growth has been a hallmark for Reddit, with annualized growth rising year after year. Quarterly growth ranged from more than 61% to nearly 78% in 2025, finishing the year with YOY revenue growth of 69.4%.

Meanwhile, the company’s earnings have improved. Since missing analyst expectations in Q1 2024—its first report after going public—Reddit has delivered seven consecutive quarterly earnings beats, including earnings per share (EPS) of $1.24 in Q4 2025, its largest beat to date on the back of record net income.

Much of the earnings growth stems from robust YOY revenue increases, a trend expected to continue and help EPS rise by nearly 95% next year, from $1.12 to $2.18 per share.

Another sign of financial strength is Reddit’s gross margin, which has been both high and steadily improving: more than 86% in 2023, above 90% in 2024 (the IPO year), and exceeding 91% in 2025.

What Wall Street Is Saying About Reddit

RDDT carries a consensus rating of Moderate Buy from 29 analysts, with 18 (62%) rating the stock a Buy. The consensus price target of $242.19 implies nearly 78% upside.

Reddit scores higher than 88% of companies evaluated by MarketBeat, which aligns with significant institutional interest in RDDT. Over the past 12 months, inflows of more than $10 billion have outpaced outflows of about $4 billion, with 726 buyers versus 303 sellers.

The current short interest of 14.70%—about $2.68 billion worth of shares—is notable but substantially lower than the $5.19 billion in shorted shares seen when short interest peaked in September 2025.

Meanwhile, for the first time since going public, insider buying, though still trailing insider selling, totaled $8.87 million in Q1.


This email is a paid advertisement provided by Huge Alerts, a third-party advertiser of MarketBeat. Why did I receive this message?


This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $14,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts’ website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).


If you need help with your subscription, feel free to email MarketBeat’s South Dakota based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2026 MarketBeat Media, LLC. 
345 N Reid Place #620, Sioux Falls, SD 57103. United States..

Featured Link: Trump Just Backed Tech That Kills Nvidia’s Moat(From Eagle Publishing)

Leave a Comment